This finding makes a case for inclusion of PALB2 in genetic testing for families with hereditary gastric cancer without CDH1 mutations, and it is possible that individuals who carry PALB2 mutations might benefit from platinum-based chemotherapy and treatment with PARP inhibitors.31 This evidence concerns the gene CDH1 and gastric cancer.